Interleukin-6 receptor expression in breast cancer with bone marrow secondaries

Abstract

Author(s): Enass Abdul Kareem Dagher Al-Saadi*

Metastatic bone marrow is one of the common bone secondary in breast cancer. This study aims to analyze the relationship between breast cancer features and the role of IL, in particular IL-6 in a bone marrow secondary setting. This is a cross-sectional study conducted at a hematology clinic, from July 2020 until June 2021. A total of 52 women with breast cancer metastasis aged between 25-58 years were included. Tumour specimens were cut into 4 mm slices and then put into 10% buffered formalin for 3 hours-6 hours. All the slides were stained automatically. Slides heated by microwave oven for 25 minutes. The mean age was 45.56 years ± 12.39 years. About 73.1% of women had positive HR while 76.9% had negative HER2neu status. In the hazard analysis, we found no significant difference in terms of age, histology, BMI, and lymph node involvement. Significant clinical factors include Positive HR status (OR=5.1), negative HER2neu status (OR=4.2) and size of the tumour (OR=3.25). The positive IL-6 indicates a higher likelihood of bone marrow metastases, which was found to be correlated with raised risk (OR=10.4). Positive HR status, tumour size and positive IL-6 status raise the risk of bone marrow metastasis in breast cancer. IL-6 is a very strong indicator for the prediction of bone marrow metastasis in breast cancer.

Share this article